BeOne Medicines (NasdaqGS:ONC) received U.S. FDA Priority Review for BRUKINSA plus rituximab in first-line mantle cell lymphoma. The chemotherapy free regimen is based on a pivotal Phase 3 trial that ...
Source LinkBeOne Medicines (NasdaqGS:ONC) received U.S. FDA Priority Review for BRUKINSA plus rituximab in first-line mantle cell lymphoma. The chemotherapy free regimen is based on a pivotal Phase 3 trial that ...
Source Link
Comments